Company news
Aardvark Therapeutics, Inc. (NASDAQ:AARD) news
Every Aardvark Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 11, 2026
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 14, 2026
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
February 27, 2026
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Name...
February 12, 2026
Aardvark Therapeutics Announces Leadership Appointments
February 12, 2026
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibili...
February 10, 2026
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
December 10, 2025
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
November 25, 2025
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
November 13, 2025
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
November 11, 2025
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
November 4, 2025
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
November 3, 2025
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 3, 2025
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
October 22, 2025
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
October 8, 2025
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 23, 2025
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
August 27, 2025
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
August 13, 2025
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA...
August 12, 2025
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
July 18, 2025
OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
July 15, 2025
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
June 24, 2025
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
May 19, 2025
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 14, 2025
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
May 7, 2025
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
March 31, 2025